Wave Life Sciences disclosed interim Phase 1 data showing its siRNA obesity candidate reduced visceral fat while maintaining or improving muscle mass markers, an outcome the company said compares favorably with low‑dose peptide competitors. The update, reported at ASH coverage and in STAT, triggered a surge in the company’s share price amid broader obesity data flow. Investigators cautioned that the study is small and that cross‑trial comparisons are imperfect; the clinical meaningfulness of the visceral fat change must be validated in larger cohorts and over longer follow‑up. Wave emphasized the mechanism targets specific adipose biology via RNA interference and highlighted muscle‑sparing as an attractive differentiator. Investors remain focused on whether fat‑specific reductions translate into durable cardiometabolic benefit and regulatory pathways for obesity indications.